Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22967657 | 0.93 | MEN1 (0.32) | — | |
| SCHEMBL22967931 | 0.93 | MEN1 (0.35) | — | |
| SCHEMBL11989201 | 0.91 | MEN1 (0.37) | — | |
| SCHEMBL22967418 | 0.91 | — | — | |
| SCHEMBL12437271 | 0.80 | LMNA (0.41) | — | |
| SCHEMBL27117066 | 0.78 | — | — | |
| SCHEMBL27426303 | 0.77 | — | — | |
| SCHEMBL15496992 | 0.76 | LMNA (0.33) | — | |
| SCHEMBL27117078 | 0.76 | SCN9A (0.35) | — | |
| SCHEMBL27426271 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217982-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-07-04 | — | — | US | disclosed |
| US-20240217982-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-07-04 | — | — | US | disclosed |
| US-20240067662-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-02-29 | — | — | US | disclosed |
| US-20240067662-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-02-29 | — | — | US | disclosed |
| US-20230348508-A1 | METAL COMPLEX, ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME, AND CONSUMER PRODUCT | BEIJING BAYI SPACE LIQUID CRYSTAL TECHNOLOGY CO. LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230348508-A1 | METAL COMPLEX, ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME, AND CONSUMER PRODUCT | BEIJING BAYI SPACE LIQUID CRYSTAL TECHNOLOGY CO. LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20210094919-A1 | KRAS MUTANT PROTEIN INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. | 2021-04-01 | — | — | US | disclosed |
| US-20210078936-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2021-03-18 | — | — | US | disclosed |
| WO-2021027943-A1 | PYRIMIDINOPYRIDAZINONE DERIVATIVE AND MEDICAL USE THEREOF | 正大天晴药业集团南京顺欣制药有限公司 | 2021-02-18 | — | — | WO | disclosed |
| US-10906867-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2021-02-02 | — | — | US | disclosed |
| US-20190321295-A1 | Method of Encapsulating a Nucleic Acid in a Lipid Nanoparticle Host | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2019-10-24 | — | — | US | disclosed |
| US-10342761-B2 | Method of encapsulating a nucleic acid in a lipid nanoparticle host | NOVARTIS AG (CH) | 2019-07-09 | — | — | US | disclosed |
| US-20170275243-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | NOVARTIS AG (CH) | 2017-09-28 | — | — | US | disclosed |
| US-20170275243-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | NOVARTIS AG (CH) | 2017-09-28 | — | — | US | disclosed |
| US-20170196809-A1 | METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2017-07-13 | — | — | US | disclosed |
| US-20170196809-A1 | METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2017-07-13 | — | — | US | disclosed |
| US-20160311759-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | NOVARTIS AG (CH) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190321295-A1 | Method of Encapsulating a Nucleic Acid in a Lipid Nanoparticle Host | POLN, POLRMT, RNGTT | KCNH2 4537/4885CHRNA7 4705/4885 |
| US-20240217982-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | KCNH2 4757/4885CHRNA7 4870/4885 |
| US-20170196809-A1 | METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST | POLN, POLRMT, RNGTT | KCNH2 4537/4885CHRNA7 4705/4885 |
| US-20210078936-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | LPAR1, LPAR4, LIPA | KCNH2 1812/4885CHRNA7 3597/4885 |
| US-20170275243-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | LRAT, LPAR4, LPAR1 | KCNH2 2006/4885CHRNA7 4201/4885 |
| US-10342761-B2 | Method of encapsulating a nucleic acid in a lipid nanoparticle host | POLN, POLRMT, RNGTT | KCNH2 4537/4885CHRNA7 4705/4885 |
| US-10906867-B2 | Lipids and lipid compositions for the delivery of active agents | LPAR1, LPAR4, LIPA | KCNH2 1812/4885CHRNA7 3597/4885 |
| US-20240067662-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | KCNH2 4689/4885CHRNA7 4871/4885 |
| US-20210094919-A1 | KRAS MUTANT PROTEIN INHIBITORS | KRAS, NRAS, APC | KCNH2 4736/4885CHRNA7 4876/4885 |
| US-20160311759-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | PHOSPHO1, SGMS1, ABCB4 | KCNH2 2033/4885CHRNA7 3850/4885 |
| US-20230348508-A1 | METAL COMPLEX, ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME, AND CONSUMER PRODUCT | TRPM5, TRPM6, TRPM2 | KCNH2 454/4885CHRNA7 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.